Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound ...
Eli Lilly said its sees growth from key treatments such as Trulicity, Taltz and Verzenio driving 2021 revenues to around $28 billion. Eli Lilly said 2020 revenues should come in between $24.2 ...
Eli Lilly now expects 2024 revenue of $42.4 billion to $43.6 billion, up from its previous forecast of $40.4 billion to $41.6 billion. The drugmaker also raised its annual profit forecast by $1.30 ...
Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise ...
If you'd invested $10,000 in Eli Lilly stock five years ago, you would have $65,900 today. That's a gain worthy of a top growth player. Lilly managed to draw the attention of a wide range of investors ...
Eli Lilly shares were marked6.6% lower in early Thursday afternoon trading following the earnings release to change hands at $319.51 each, erasing all of the stock's six-month gains.
The collaboration, which gives Lilly access to Aktis’ technology in return for $60 million, adds to a flurry of dealmaking in the radiopharma field.
Eli Lilly and Company LLY posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. The pharmaceutical giant raised its outlook for 2024 on rapidly climbing ...
(Reuters) -Explosive demand and increased manufacturing capacity for Eli Lilly (NYSE:LLY)'s weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday ...
(Reuters) -Eli Lilly raised its annual revenue forecast by $2 billion on Tuesday due to strong demand and plans to increase production of its weight-loss treatment Zepbound and related diabetes drug ...
Eli Lilly raised both ends of its 2024 revenue forecast by $2 billion and now expects $42.4 billion to $43.6 billion for the year. The drugmaker also raised its annual profit forecast by $1.30 per ...